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Abstract: Neuroblastoma (NBM) is a deadly form of solid tumor mostly observed in the pediatric
age. Although survival rates largely differ depending on host factors and tumor-related features,
treatment for clinically aggressive forms of NBM remains challenging. Scientific advances are
paving the way to improved and safer therapeutic protocols, and immunotherapy is quickly rising
as a promising treatment that is potentially safer and complementary to traditionally adopted
surgical procedures, chemotherapy and radiotherapy. Improving therapeutic outcomes requires
new approaches to be explored and validated. In-silico predictive models based on analysis of a
plethora of data have been proposed by Lombardo et al. as an innovative tool for more efficacious
immunotherapy against NBM. In particular, knowledge gained on intracellular signaling pathways
linked to the development of NBM was used to predict how the different phenotypes could be
modulated to respond to anti-programmed cell death-ligand-1 (PD-L1)/programmed cell death-1
(PD-1) immunotherapy. Prediction or forecasting are important targets of artificial intelligence
and machine learning. Hopefully, similar systems could provide a reliable opportunity for a more
targeted approach in the near future.
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Amongst the deadly diseases affecting children, neuroblastoma (NBM) accounts for 15% of
all deaths in pediatric age [1]. It is the most common tumor of the sympathetic nervous system,
often evidenced as an extracranial mass that is most frequently encountered in the adrenal glands [2].
NBM cell lines are frequently used for basic research that investigates synaptic function and the relative
pharmacological modulation [3,4]. This approach has been widely applied in literature to explore
fundamental processes of the nervous system and neurodegenerative trajectories [5,6]. It is estimated
that 6% of pediatric cancers are due to NBM, with a mean age of diagnosis of 1–2 years old and rare over
the age of 10 [7,8]. However, the behavior of this tumor dramatically changes according to both host
factors, such as age at diagnosis, and tumor biology, ranging from a high probability of spontaneous
regression to 41.5% survival five years after diagnosis [9].
For this reason, a huge effort has been made by many researchers and clinicians in order to
perform a risk stratification of patients into groups with low, intermediate, and high risk; moreover,
it has been recently proposed to add a ‘ultra-high risk’ group that causes “death from disease within
18 months of diagnosis” [10].
According to the latest data, about 50% of patients affected by NBM are classified as a high-risk
group [11]. As a consequence, early identification of high or ultra-high-risk groups should lead to
more aggressive treatments, whereas the goal of recognizing low-risk groups is to avoid unnecessary
treatments and ultimately minimize adverse effects [12]. Among biological factors related to higher
risk, in 2009 the International Neuroblastoma Risk Group (INRG) mentioned tumor histology and its
grade of differentiation, DNA index (ploidy) and MYCN oncogene amplification (MYCN-A) [13].
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More recently, a better understanding of the biology and pathophysiology of NBM has been
reached thanks to the identification of intracellular molecular cascades and signaling pathways.
These have been associated with the control of cell growth and division, mutations, phenotypic
changes and ultimately responsible for the development of cancer [14]. The identification of immune
checkpoints, playing a crucial role in the transformative potential of tumors, has quickly boosted
the development of immunotherapy approaches to different cancer types, for instance acting on
excessive damage to tissues induced by inflammation [15].
It has been speculated that programmed cell death-protein-1 (PD-1) can modulate immune
response by binding to programmed cell death-ligand-1 (PD-L1), a transmembrane protein expressed
in T cells. On this point, natural killer cells (NK) are promising immune effectors in anticancer responses
mediated by T cells [11]. This immune checkpoint, with associated signaling pathways, has been
identified as a target for anticancer drugs for monoclonal antibodies, nivolumab and pembrolizumab,
and small molecules [16]. When combined with anti-GD2 antibodies, nivolumab has been proven to be
effective in a mouse model of NBM [17]. Further research described response rates to the PD-1/PD-L1
axis blockade, suggesting that PD-L1 expression may also serve as a predictive marker in small-cell
lung cancer and NBM [18,19].
Altogether, these findings point to the possibility of combining the computing power and clinical
data to realize predictions of the response to immunotherapy treatments. In order to identify
and assess the impact of specific parameters and targets, predictive models provide solid bases for
developing well-directed and targeted approaches. Specifically, in the paper by Lombardo et al. [20],
Michelis–Menten modified equations were employed to evaluate the parameters that mostly affect
the expression of PD-L1 by means of computer-based sensitivity analyses. The results of this study
revealed the different influence of ALK- and EGFR-pathways in the expression of PDL-1, depending
on the genetic targets implicated. For instance, this kind of prediction indicates that patients with
ALK1174L-mutated tumors would better respond to a therapy with nivolumab rather than crizotinib.
It is worth noting that in a very recent study two NBM patients were treated with a combination
of nivolumab and anti-disialoganglioside antibody dinutuximab beta (DB), which is known to exert its
function by modulating PDL-1 expression. Both patients had a remarkable improvement of clinical
picture [21]. Accordingly, the most up-to-date studies on both nivolumab and pembrolizumab proved
their safety as an anticancer treatment for pediatric patients. Nonetheless, despite their promising
preclinical profile, they showed notable effects only on lymphoma and not on NBM patients. In detail,
nivolumab was used in solid tumors without pre-screening for PDL-1 and only 7% of NBM (one out
of 15 patients) was PDL-1 positive [22]. Pembrolizumab was instead used in young patients who
were tumor PDL-1 positive, but the response rate was similar to that obtained in the non PDL-1
screened population, thus leading the authors to conclude “PD-L1 expression alone is not sufficient
as a biomarker for the selection of paediatric patients who are likely to respond to PD-1 checkpoint
inhibitors” [23].
Taken together, the aforementioned papers give strength to the Lombardo model [20], which
could explain these apparently contrasting findings. According to this model, the ALK gene is the main
determinant of PDL-1 expression. Hence, in patients who are both PDL-1 positive and a carrier of
ALK1174L mutation, nivolumab results in being more effective with respect to patients that do not
carry this mutation.
We believe that this new approach, based on in-silico simulation, has great potential especially in
those illnesses in which precision medicine has a primary role, like NBM [12].
Moreover, this network model of molecular pathways could generate a sufficient bulk of simulated
data of interaction, when real ones are unavailable. This can be put into practice in order to significantly
increase the reliability of decision-making algorithms based on machine learning (ML), which strongly
depends on the amount of datasets involved. This would begin a virtuous cycle, allowing faster
experimentation and targeted treatment. Indeed, a recent work by Schmauch et al. [24] showed that
the He2RNA model can be trained to correctly predict RNA sequences profile from whole-slide images
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of different types of tumor. Exploiting the power of ML and computational models of molecular
pathways would set the basis for a future in computer-aided precision medicine.
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